Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid

Anticancer Res. 2010 Sep;30(9):3565-71.

Abstract

Background: Although zoledronic acid (ZOL) has been reported to show anti-tumour effects on various malignant tumours, few studies have reported the molecular mechanisms of resistance to ZOL.

Materials and methods: A drug-resistant cell line was developed by repeatedly treating human osteosarcoma cell line HOS with ZOL. Expression status of drug resistance-related molecules including ATP-binding cassette (ABC) and heat-shock protein 27 (HSP27) was confirmed in order to analyse molecular mechanisms of the drug resistance.

Results: Repeated treatment with ZOL induced drug resistance with down-regulation of apoptosis in the resistant cell line. Although ABC expression was down-regulated, up-regulation of HSP27 in the resistant cell line was confirmed. The resistance was overcome by HSP27 silencing.

Conclusion: Resistance to ZOL in osteosarcoma cells may be induced by a molecular mechanism different from conventional efflux pump-based resistance. Up-regulation of HSP27 expression may play a role in the development of ZOL resistance in HOS cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Apoptosis / genetics
  • Cell Line, Tumor
  • Diphosphonates / pharmacology*
  • Drug Resistance, Neoplasm / genetics*
  • HSP27 Heat-Shock Proteins / genetics
  • HSP27 Heat-Shock Proteins / metabolism*
  • Humans
  • Imidazoles / pharmacology*
  • Immunoblotting
  • Osteosarcoma / genetics
  • Osteosarcoma / metabolism*
  • RNA Interference
  • Reverse Transcriptase Polymerase Chain Reaction
  • Zoledronic Acid

Substances

  • Antineoplastic Agents
  • Diphosphonates
  • HSP27 Heat-Shock Proteins
  • Imidazoles
  • Zoledronic Acid